POST 18th_ELSF
​> ATTENDEES​
​​> INVESTORS​
> PRESENTERS​
​> SPONSORS​
​> SUPPORTERS​

20-minute presenters

Anixa Biosciences, Inc.
[​NASDAQ: ANIX]

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.

​Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization.

www.anixa.com

Anocca AB

Anocca is a fully integrated biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its unique discovery engine uses programmable human cells to recreate and manipulate T cell immunity. This proprietary technology scales TCR-T cell therapy development, allowing the systematic generation of personalised treatments for the broadest patient populations.

Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and in-house cGMP manufacturing and process development facilities. All Anocca’s therapeutic TCRs are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca’s facilities in Sweden.

ANOC-001 is the first product to enter human trials from Anocca’s robust T-cell receptor T-cell therapy (TCR-T) pipeline and, subject to approval, the trial will start during Q2, 2025.

www.anocca.com

ARTCLINE GmbH

ARTCLINE GmbH was founded as a spin-off from the University of Rostock. The company is developing innovative diagnostic and therapeutic procedures for intensive care medicine. The focus is on a novel immune cell-based extracorporeal procedure for the treatment of septic shock – one of the major challenges for global health systems.

Developed by immunologists and dialysis specialists, the ARTICE® therapy uses immune cells from healthy donors to temporarily take over some of the functions of the patient’s impaired immune system and reactivate it.

www.artcline.de

BioInvent International AB
[STO: BINV]

BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline and providing licensing and partnering opportunities.

BioInvent International is at the forefront of biotechnology innovation, with a strong pipeline of promising therapies."" - Analyst at Kempen.

www.bioinvent.com

CNS Pharmaceuticals, Inc.
[​NASDAQ: CNSP]

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

www.cnspharma.com

FoRx Therapeutics AG

FoRx Therapeutics is a preclinical-stage company dedicated to the discovery and development of innovative, next-generation oncology drugs that target DNA Damage Response (DDR) pathways in cancer. 

Our lead program is a potent and selective PARG inhibitor (FORX-428) with strong evidence for best-in-class potential, which was recently declared as Development Candidate and is currently progressing to IND.

www.forxtherapeutics.com

Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives, and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer’s disease – Galimedix’s initial areas of focus. The Company’s approach targets misfolded Aβ monomers, thus preventing the formation of toxic oligomers and protofibrils.  Recent approvals and promising Phase 3 results of anti-Aβ drugs have validated them as a key target in Alzheimer’s disease.  Many studies have also indicated that these Aβ aggregates are an underlying cause of neurodegenerative diseases of the eye. Compelling pre-clinical data support the potential of Galimedix’s product candidates to slow or stop neurodegeneration and restore lost neuronal function. Recruitment of patients in a pivotal Phase 2 study in dry AMD with the lead program, topical GAL-101, has just started, The oral first-in-human Phase 1 study is progressing as planned since  November 2024. Upon successful completion of  phase 1, clinical phase 2 studies in several indications, including Alzheimer’s are planned for 2026.​

www.galimedix.com

iOmx Therapeutics AG

iOmx is a clinical-stage company that harnesses deep tumor immunology insights to generate novel treatments for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity, iOmx is creating potential new backbone therapies in a modality-open fashion. By applying its comprehensive drug discovery & development expertise iOmx is committed to shaping the future of cancer therapy.

iOmx was founded in 2016 and is based in Munich. iOmx is backed by international venture capital investors, such as ATHOS, Sofinnova Partners, Wellington Partners, MIG Capital as well as M Ventures. The company closed a €65m Series B in September 2021.

www.iomx.com

MetrioPharm AG

MetrioPharm is a Swiss clinical-stage biotech company that has developed a platform of oral small molecule immune modulators that normalize the pathologically dysregulated (reprogrammed) mitochondrial energy metabolism in macrophages and other immune cells without being immunosuppressive. This plays an important role in most inflammatory and infectious diseases.

MetrioPharm's lead candidate MP1032 has a unique, self-regulating mechanism of action that makes it a first-in-class ROS (Reactive Oxygen Species) scavenger that reduces excessive intracellular ROS (intracellular oxidative stress) WITHOUT (!) interfering with the physiological (normal) ROS levels of other cells. ROS are essential for cell signaling.

MP1032 has demonstrated broad-spectrum anti-inflammatory and antiinfectious activity in three completed Phase IIa clinical proof-of-concept studies in Psoriasis and COVID-19 involving a total of 234 patients treated with MP1032.

​In addition, MP1032 has shown strong efficacy data in preclinical in vivo studies in other inflammatory diseases such as Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Diseases, Sepsis and, most recently, Duchenne Muscular Dystrophy. As a monotherapy, MP1032 has therapeutic effects similar to corticosteroids, but without serious side effects.

MP1032 in combination with ultra-low dose corticosteroids has the potential to replace the current standard of care, high dose corticosteroid therapy, with increased efficacy (2.5 times the high dose) and significantly reduced side effects.

MP1032 has also demonstrated a broad host-directed antiviral and antibacterial activity in preclinical and clinical studies, which would be essential for improving future pandemic preparedness.

MetrioPharm is initially focusing its anti-inflammatory drug development on rare diseases such as Duchenne Muscular Dystrophy. In this indication, patients are treated for many years or even decades with high-dose corticosteroids (cortisone-based therapeutics) as standard anti-inflammatory therapy, which typically leads to severe side effects. The focus on orphan indications is the fastest route to conditional marketing authorization by the EMA and accelerated approval by the FDA for MP1032.

www.metriopharm.com

Minoryx Therapeutics

Minoryx Therapeutics is a Spanish registration stage biotech company focusing on the development of leriglitazone for X-linked adrenoleukodystrophy (X-ALD) and other orphan CNS diseases.Minoryx was founded in 2011 has so far raised more than €120 million and has reached licensing agreements for EU (Neuraxpharm) and China (Sperogenix).​

www.minoryx.com

RedHill Biopharma Ltd.
[​Nasdaq: RDHL]

RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on U.S development and commercialization of drugs for gastrointestinal diseases, infectious diseases, medical countermeasures, and oncology. RedHill has a robust development pipeline with multiple near-term milestones, as well as a U.S. commercial footprint, promoting the gastrointestinal drug Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection.

www.redhillbio.com

SpyBiotech Inc.​

SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and chronic diseases. The company was spun out of the University of Oxford in 2017 by Oxford Science Enterprises (OSE) and Google Ventures (GV). The company raised $32.5 million in a Series A equity financing in 2021. Based on science developed at the University of Oxford, SpyBiotech’s novel vaccine platform is based on a proprietary protein “superglue” technology which binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize and sub-license the SpyTag/SpyCatcher and related “superglue” technologies in vaccine development.​

www.spybiotech.com

XYone Therapeutics Inc.​

XYone Therapeutics was established in 2021 to translate innovative discoveries spun out of Dana Farber Cancer Center/Harvard Univ. and Boston Univ. Based in a Boston Suburb, XYone is developing First-In-Class ADCs targeting tumor-anchored Mucin 1 (MUC1-C).

XYone has raised $17.5 million and received several, multimillion-dollar, non-dilutive innovation grants from NIH. Now we are initiating a $38 million Series A round to accelerate clinical development of the ADC oncology pipeline​​.

Two MUC1-C targeting ADCs in advanced stages of development:
XYA01 (MMAE payload ADC): Awarded acceptance into the NCI NExT program of the National Cancer Institute (NIH, US). NCI will generate all the IND enabling data, GMP production, and IND filing with the FDA; XYone retains all the rights on the drug. Non-dilutive contribution of ~$12-15MM USD. IND planned for early 2026.

XYA02 (Exatecan payload ADC): GMP development initiated, IND planned for Q2, 2026.

mAbs licensed to Posieda/Roche for CAR-cell therapies: entitled to ~$71MM milestones + royalties.

Compelling pipeline of T-Cell engager, and multispecific anti-tumor therapeutics.

www.xyonetx.com

10-minute presenters

AATec Medical GmbH

AATec develops novel biopharmaceuticals for major respiratory inflammatory diseases such as COPD, bronchiectasis, asthma, and respiratory infections. The first indication for clinical development will be non-CF bronchiectasis.

Our product platform is based on a novel version of alpha-1 antitrypsin for inhalation, a multimodal anti-protease and immuno-modulator with superior therapeutic effects and a new inhaler device.

The technology platform has been established and preclinical proof-of-concept has been shown. The first clinical study in non-CF bronchiectasis is planned to start in 2025.

www.aatec-medical.com

Abalos Therapeutics GmbH

Abalos develops a a transformative  approach to overcome cancer immunotherapy hurdles and break down solid tumors. 

Abalos aims to raise EUR 5-10 to expand our pipeline and to broaden the clinical trial with our lead product ABX-001 (trial to start Q2 2025). Abalos offers a unique investment opportunity that will drive multiple milestones in the next 12-24 months, including early clinical validation of our technology and broad expansion of our pipeline. 

Abalos products are based on the AdaptInnate platform. This platform is rationally designed to induce both broad innate and adaptive immune responses. It engages all relevant components of the immune system in a body-wide and concerted attack against the primary tumor and distant metastases. The unique advantages of our technology establish a new level of immune system activation to clear and control cancer. 

Our lead product  ABX-001 has shown strong  efficacy in pre-clinical studies against a broad range of tumors and has a very clean pre-clinical safety profile, including excellent safety at high doses in non-human primate studies. A robust and scalable cGMP manufacturing process has been established. 

Clinical trials with ABX-001 will start in Q2 2025, with first results expected before the end of this year. Based on its unique mechanism of action, ABX-011 has potential benefit  in a broad range of cancers, including tumors that are not responsive to immuno-therapy or that have developed resistance to checkpoint inhibitors. ABX-001 is well suited for monotherapy, but is also well positioned to be combined with other modalities such as chemotherapy, CPIs, T-cell engangers, ADCs and cell therapy.

Beyond ABX-001, Abalos is developing the next clinical candidate, that adds specific activity to the benefits offered already by ABX-001. Pre-clinical PoC for the next compound is expected in the coming 12 months.

www.abalos-tx.com

ActiTrexx GmbH

We are a clinical Phase I/II biotech company focused on the development of a platform technology for cellular and biologic therapies to treat overshooting T cell mediated autoimmune and autoinflammatory diseases with high medical unmet needs.

Our cell therapeutic approach is unique being ready to use within 24 hrs (ultrafast manufacturing process), is very cost efficient and IP protected.

With our lead cellular product, Actileucel (activated regulatory T cells), our goal is to prevent GvHD at an early stage and to provide a curative therapy with few side effects for patients undergoing blood stem cell transplantation for the first time. Actileucel is a safe and efficient treatment option that addresses a significant unmet medical need. First patients have been treated with a very good safety profile.

Actileucel has the potential to overcome current risks and limitations inherent in stem cell transplantation.

In addition, due to our platform technology Actileucel has a very high upside potential.

www.actitrexx.de

Alder Therapeutics AB

At Alder Therapeutics we develop affordable regenerative stem cell therapies.

Traditional approaches to bringing cell therapies to market are fraught with challenges. Alder’s unique drug development philosophy de-risks development bringing advanced cell therapies to market, faster, and more reliably.

Our two promising allogeneic therapies in the pipeline are supported by a comprehensive preclinical data package showing they treat disease in relevant large animal models. We have received supportive feedback from both FDA and EMA for our CMC and pre-clinical programs. In addition, our market access analysis shows a huge potential ROI as the gap between our COG (1000€) and reimbursement (200 000€) is large. In addition, we have additional barriers to entry in addition to our IP.

We are raising funds to deliver clinical proof-of-concept in Retinitis Pigmentosa for our lead program.

Alder Therapeutics is a private Swedish pre-clinical phase cell therapy development company started in 20222 with two animal proof-of-concept allogeneic stem cell therapy programs in the pipeline. Our lead program ALD01 aims to treat a rare inherited degenerative eye disease (Retinitis Pigmentosa) in a unique mutation agnostic fashion. Our second program intends to treat Heart Failure.

www.aldertx.com

AM-Pharma B.V.​

AM-Pharma, a private biotech company based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa as two distinct products: 1) for prevention and treatment of acute kidney injury and 2) as an enzyme replacement therapy administered sc for the rare disease hypophosphatasia.

www.am-pharma.com

Antabio SAS

Antabio is a privately held clinical stage biopharmaceutical company developing novel treatments of drug-resistant bacterial infections caused by WHO/CDC critical priority pathogens, with a particular focus on life-threatening respiratory infections.

www.antabio.com

AVEROA SAS

AVEROA PHARMA is an emerging innovative company, based in France focused on the development and registration of drugs with high interest to patients with kidney or metabolic diseases.

The company has a pipeline of highly innovative products, some of them in early research and development ensuring a high potential valuation at exit and others that require very limited investment but contribute significantly to the financing of the pipeline while avoiding dilution to our future investors.

AVEROA PHARMA is a company with clinical stage assets, Xoanacyl® is currently in the European registration process with an expected launch in Q1 2026, while AVA2171, addressing a rare kidney disease, should be in the registration phase in 2026/2027. AVA2206, a compound about to enter Phase I clinical trials, has the potential to target multiple rare diseases and could be accompanied by a medical device (AVA2065) to aid in the diagnosis and monitoring of those diseases.

The company employees are experts in clinical development, regulatory management, strategy and market access.

The company is looking to raise funding.

www.averoa-pharma.org

biotx.ai GmbH

biotx.ai - Industrializing causal inference in drug development.

The gold standard for establishing causality is the prospective, randomized, placebo-controlled trial, which is necessary for drug testing. Outside of biomedicine, due to time and cost constraints, causality can be investigated prospectively only to a limited extent. Thus, statistical methods have been developed to derive causal relationships from observational data retrospectively, known as causal inference; when combined with machine learning, this is referred to as causal AI.

biotx.ai has developed a groundbreaking platform that scales causal inference for the biotech industry. By curating a comprehensive catalog based on 9,539 datasets including 22,376,782 cases across 3,303 diseases, biotx.ai stands at the forefront of data-driven drug discovery. With an initial dataset of 23,280 genes and more than 10,000 biomarkers, biotx.ai enhances these entries with annotations of approved drug targets.

The platform leverages advanced machine learning to identify clusters, pinpointing the essential causal relationships of drug targets. This process connects drug targets directly to disease biology, uncovering novel candidates with verified causal links to various health conditions.

www.biotx.ai

CIS BIOPHARMA AG

CIS BIOPHARMA helps cancer patients live longer and better lives.
​
We are a biotechnology company dedicated to revolutionizing cancer treatment by harnessing the power of antibody-drug conjugates, ADCs and radioligand therapies, RLTs. While our assets have pan-cancer potential, we have a clear focus on lung cancer and brain tumors as primary indications. Our state-of-the-art laboratories are located in the area of Basel, Switzerland, a global hub for life sciences innovation.

www.cisbiopharma.com

Convert Pharmaceuticals SA

Clinical Phase 1 & 2 company developing therapeutics to target tumor hypoxia to overcome cancer treatment resistance and 2x immunotherapy efficacy.

www.convertpharma.com

Innovent Biologics
[HKEX: 01801]

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 3 new drug applications (NDA) under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Sanofi, Incyte, Adimab and LG Chem.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

www.innoventbio.com

invIOs GmbH

invIOs is a privately held biotech company focused on discovering and developing innovative cancer immunotherapies, currently in collaboration for glioblastoma with the Dana-Farber Cancer Institute, Boston, Mass. (Harvard Medical School).

Our projects:
• invIOs’s clinically validated proprietary cell therapy platform, EPiC, which enables rapid treatment of patients in an out-patient setting using their fresh immune cells using a validated, safe and optimised process.
• APN401 is a cell therapy and is the first candidate treatment using the EPiC platform. APN401 has completed 3 Phase 1 trials against various solid tumors targeting cbl-b. 
• INV441 is a cell therapy to activate tumor cell killing via immune cells from the tumor (TILs) for treatment of glioblastoma. In preclinical-stage, INV441 utilizes the EPiC platform. Start clinical phase 1 study in glioblastoma is planned for 2024.
• INV501 is a novel, orally available, first-in-class small molecule activating the immune system only in an antigen-specific context. In preclinical-stage, INV501 shows strong inhibition of tumor growth with 100% response rate and survival rates of up to 90% in rodent tumor models. INV501 data show immunological memory and long term protection beyond end of treatment. In addition, INV501 has a synergistic effect with checkpoint inhibitors and prolongs CAR T cell cytotoxicity.

www.invios.com

Laverock Therapeutics Ltd.

Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally-occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting regenerative medicine and oncology – and through partnerships.

www.laverocktx.com

Lead Pharma

Lead Pharma is a leading pharmaceutical Research & Development company discovering, designing, and developing innovative small-molecule therapies in three therapeutic areas:
1) Immunology
2) Oncology 
3) Metabolic disease.

A clinical-stage company with strong capabilities and unparalleled expertise in the discovery and optimization of novel chemotypes developing a differentiated pipeline with first-in-class and best-in-class projects.

We would like to meet with Pharma companies to explore partnering opportunities and with VCs to explore strategic investment opportunities.

www.leadpharma.com

LightOx Ltd.

LightOx, headquartered in the UK, is at the forefront of developing innovative light-activated therapies, with a primary focus on treating early-stage oral cancers. Their lead candidate, LXD191, is a novel photosensitizing agent designed for topical application to pre-cancerous lesions in the oral cavity. Upon activation by a specific wavelength of light, LXD191 induces  targeted cell death eliminating cancerous tissues while minimising damage to surrounding healthy cells.

This process involves a clinician applying a gel containing LXD191 directly to the affected area. The drug is activated using a simple light offering a less invasive alternative to traditional surgical procedures, aiming to reduce patient discomfort and improve recovery times.

Pre-clinical studies have demonstrated promising results, with LXD191 showing significant efficacy in inducing cell death in cancerous tissues upon light activation. Building on these findings, LightOx has collaborated with the clinical team at the Liverpool Head and Neck Centre and formulation specialists to develop a suitable gel for clinical use.

In recognition of their groundbreaking work, LightOx has won multiple non dilutive grants from the UK. This funding supports the advancement of LXD191 through final pre-clinical phases and facilitates collaboration with clinical partners to develop a “chair-side” treatment for patients with early-stage oral cancers.

LightOx will raise £10M in a Series A round to initiate Phase I/IIa clinical trials for LXD191 in 2026, aiming to provide a minimally invasive treatment option for patients with oral dysplasia and reduce their risk of developing mouth cancer. The company’s innovative approach has the potential to transform the management of early-stage oral cancers, offering a convenient and effective alternative to surgery.

LightOx second asset is a light-activated antimicrobial gel specifically designed to treat chronic wounds. LXD231, has shown to be active against the WHO, ESKAPE pathogens.

www.lightox.co.uk

​LimmaTech Biologics AG

LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust company pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide.​

www.lmtbio.com

Mabylon AG

Mabylon, a Swiss Biotech company, builds on its understanding of antibody responses in allergic patients to develop single multispecific antibody molecules that neutralize the allergens and prevent allergic reactions.

The first of such products, MY006, is a potent trispecific antibody with half-life extension being developed for peanut allergy and poised to start clinical trials in 2025. MY006 is designed to provide rapid, safe, and long-lasting protection against peanut allergen exposure. 

A clinically-validated MoA and a high-yielding and stable product produced by Pfizer, offer together a greatly de-risked development path. The focus of our current fundraising is to show efficacy POC in a phase 1b, an inflection point rendered even more valuable by the adoption of the same endpoint in early and late clinical development.

Shortly following, MY010 and MY011 target multiple tree pollens or grass pollens respectively, to relief seasonal allergy symptoms with one single injection before start of the season. 

Mabylon is positioned to revolutionize the allergy therapeutic landscape by providing effective therapies with simple dosing, allowing allergic patients to regain control of their lives.

www.mabylon.com

Macomics Ltd.

At Macomics, we are identifying first in class targets in fibrotic and inflammatory diseases using our novel gene editable iPSC disease models and proprietary patient bioinformatic atlas. We translate complex human data-sets into genetically validated therapeutic targets with a focus delivering new medicines targeting macrophage and microglia driven disease.

Macomics has a fully differentiated antibody in IND studies with first-in-class potential in castrate-resistant prostate cancer. We are also leveraging our technology to advance an exciting pipeline antibody therapeutic programs in fibrotic disease and to genetically validate novel microglia targets.

We select targets on the basis of unbiased functional genomics leveraging our patented gene editing methods with libraries trained by our patient atlas, reducing translation risk through genetic target validation in disease relevant models.

www.macomics.com

NEC Bio B.V.
[​TYO: 6701]

NEC Bio B.V. under the umbrella of NEC Corporation-a notable ICT conglomerate in Japan is a clinical stage biotech company focused on the development of artificial intelligence driven therapies within immuno-oncology and infectious disease vaccines. Our personalized neoantigen cancer vaccines are currently being investigated in the clinic with promising preliminary data published at AACR 2024. We have also developed a proprietary BCE hunt technology for Ab discovery.​

www.nec-bio.com

​PhoreMost Ltd.

PhoreMost is progressing a pipeline of ‘next-generation’ degrader therapeutics.

Targeted Protein Degradation (TPD) is a promising new way to eliminate toxic or disease-associated targets from cells, with degradation-based therapies now becoming an integral approach to tackling undruggable targets. However, despite there being over 600 known E3 ligases, the pharma industry is currently reliant upon a very small number, such as Cereblon, for degrader-based drug development. 

PhoreMost is unlocking the full potential of TPD and has pioneered the use of mini-protein based engineering via its proprietary target identification platforms, SITESEEKER® and GlueSEEKER™ towards developing novel therapeutic approaches to TPD. The Company has progressed multiple next-generation ligase programmes through proof-of-concept and is advancing multiple Oncology and Inflammation degrader assets towards preclinical studies.

PhoreMost also has a number of disclosed alliances with partners, including: Roche, Boehringer Ingelheim and Sentinel Oncology.

www.phoremost.com

Reconnect Labs AG

Reconnect Labs is a Swiss, clinical stage biopharmaceutical company on a mission to change the paradigm in mental health from symptomatic to curative treatments.

Leveraging decades of expertise and a world-class network of leaders in clinical drug development, Reconnect Labs is progressing the development of rapid-acting precision psychiatry designed phase 2 drug candidates with the potential to transform the treatment landscape for insomnia and psychiatric conditions such as PTSD and substance use disorders based on new paradigms:
1. Treating difficult mental health conditions, such as PTSD, via treating the dysfunctional sleep of these patients (Asset: RE03)
2. A novel and differentiated precision psychiatry paradigm for prediction of responders to our psychedelic drug candidates via psychological markers (already at >80% accuracy with limited data sets), in combination with psychedelic drug assets designed to have sharpened and fully controllable therapeutic psychoactive effects (Assets: RE01 and RE02).

www.reconnect-labs.com

Sarcura GmbH

Sarcura, an Austrian deep-tech startup, is pioneering the development of CellFAB—a miniaturized, autonomous manufacturing platform designed to execute all unit operations within a closed cartridge.

By leveraging cutting-edge silicon chip technology, we seamlessly integrate real-time analytics to enable the precise selection of highly specific cell populations within a compact footprint.

Our advanced analytical capabilities generate process insights, empowering AI and machine learning to precisely control complex living therapies—eliminating the need for human intervention.

This approach ensures true scalability, making affordable, mass-customized cell therapies a reality.

www.sarcura.com

Spago Nanomedical AB
[​STO: SPAGO]

Spago Nanomedical is a Swedish clinical stage company focusing on development of novel radiopharmaceuticals for expanded treatment of multiple solid tumor indications.

www.pagonanomedical.se

SpikImm SARL

SpikImm is a spin off from Insitut Pasteur, and has access to its research capabilities. The company is focussed on Long acting mAbs to give immunocompromised patients passive immunity (that normally vaccines provide).

Our lead program is aimed at protecting Kidney Transplant & HCST patients from BK virus and is also applicable to patiemnts at risk of JC virus (which is lethal).

We are run by a highly experienced (and older) team of experts, in a virtual manner.

Funding to date by Truffle Capital, but now undertaking a significant raise with Stragetic & VC investors at termsheet stage.

www.spikimm.com

Sapreme Technologies BV

Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues. The technology is based on natural plant endosomal escape enhancers that are conjugated to any large molecule of interest and targeting ligands such as GalNAc and antibodies for cell- and tissue-specific delivery.

We have successfully translated the technology in non-human primates and have in vivo PoCs in muscle, heart, kidney and tumor tissue. Sapreme is now building a pipeline, and our lead candidate is designed to become best-in-class for Duchenne by using a transferrin receptor 1-antibody coupled to our endosomal escape enhancer to enable intracellular delivery of the RNA exon-skipping payload.

The company is now raising a €50 M Series A to develop our own pipeline beyond clinical translation in 2027. We are also pursuing strategic partnerships on our technology to co-develop products with select pharma/biotech companies and recently signed our first option deal, for an exclusive license on our technology to enable RNA therapeutics in kidney.

www.sapreme-technologies.com

STIMIT AG

STIMIT is revolutionizing respiratory & critical care: we use neurostimulation to empower patients to breathe. STIMIT discovered a greenfield beyond heart and brain neurostimulation: lung-related neurostimulation is the new breakthrough in this field.

A healthy person breathes 20,000 times a day, while ventilated patients in the intensive care unit frequently do not breathe at all (passive ventilation instead of active breathing). The central respiratory muscle, the diaphragm, is lost in these patients by up to 50% in the first 3 days, resulting in prolonged ventilation and ICU complications. This is a multi-billion dollar market on each continent, STIMIT has a validated value-based business model.

Diaphragm neurostimulation is important for lung health, for brain function, and venous backflow to the heart.

www.stimit.com

Stromal Therapeutics AG

"Stromal Therapeutics AG is a Swiss biotech company founded in 2018, focused on developing immunotherapies against a broad range of chronic diseases by targeting the tissue stroma. The stroma comprises cells such as fibroblasts and endothelial cells that build the infrastructure of an organ, ensuring its form, nutrient and oxygen supply. Stromal cells produce tissue cytokines that steer the function of immune cells at sites of inflammation, identifying them as drugable targets to resolve inflammation in chronic diseases. Stromal Therapeutics’ lead compound targets a tissue cytokine pathway that is involved in cardiac inflammation and fibrosis.

The founders have extensive expertise in stromal cell immunobiology exemplified by high-ranking publications in journals such as Science, Nature Immunology and Immunity and prestigious grants. Prof. Burkhard Ludewig, one of the academic founders and current president of the board, is the recipient of the European Research Council Advanced Grant 2020, awarded to study the molecular and cellular basis of inflammatory myocardial disease. The world-leading academic expertise of the founders positions Stromal Therapeutics at the forefront of drug development in the field of cardiac inflammatory diseases.

The company has developed antibody-based lead compounds against an important tissue cytokine pathway and has elaborated the mechanism of action in proof-of-principle models generated by the founders. The lead antibody compound that has been successfully humanized, cures inflammatory cardiomyopathy and prevent cardiac fibrosis. Targeting the tissue stroma in cardiac inflammatory diseases is an innovative strategy to therapeutically target inflammatory heart disease, and potentially heart failure.

www.stromaltherapeutics.ch

T-knife Therapeutics, Inc.

T-knife is a biopharmaceutical company developing T cell-based immunotherapies that deliver broad, deep and durable responses to solid tumor cancer patients.

The company’s lead program, TK-6302, is a Supercharged PRAME targeting TCR-T rationally designed with novel enhancements to improve T cell fitness and persistence and to overcome the immunosuppressive tumor micro-environment.

T-knife is supported by a leading group of international investors, including Andera Partners, EQT Life Sciences, RA Capital Management and Versant Ventures and is seeking investment for its next round of financing.

www.t-knife.com

Telum Therapeutics SL

Telum Therapeutics SL is a global biotechnology company dedicated to drug discovery and the development of innovative alternatives to traditional antibiotics. Our cutting-edge approach leverages naturally occurring bacterial lysins combined with synthetic biology and machine learning to design antibacterial lysins that precisely target and eliminate multidrug-resistant bacteria.

Lytic enzymes have been widely recognized as one of the most promising alternatives to conventional antibiotics. To harness their full potential, Telum is data mining its vast collection of proprietary metagenomes, to develop novel bacterial lysins that are significantly more potent and refractory to the emergence of bacterial resistance.

Telum’s APEXp platform enables the development of a robust modular library of optimized lysins, allowing for the rapid design of follow-on precision-engineered antimicrobials that delivers a sustained and effective response against the emergence of bacterial resistance.

Our mission is to bring hope to patients suffering from drug-resistant infections by developing next-generation antimicrobial agents that redefine the future of antibiotic drug development and help provide an effective and durable response to the global antimicrobial resistance crisis.

www.telumtherapeutics.com

TME Pharma
[​EPA: ALTME]

TME Pharma is a clinical-stage biotech company developing innovative therapies for aggressive cancers, focusing on the tumor microenvironment (TME).

Our lead compound, NOX-A12, targets CXCL12 and has received Fast Track designation from the FDA for newly diagnosed, chemotherapy-resistant glioblastoma. In a Phase 1/2 trial, NOX-A12 combined with anti-VEGF and radiotherapy significantly increased survival compared to the standard of care reference cohort (p=0.003, Hazard Ratio: 0.30) and patients receiving NOX-A12 with radiotherapy alone (p=0.021, Hazard Ratio: 0.34). Median survival improved from 9.5 months to 19.9 months. A randomized, controlled Phase 2 trial is approved in the US and Germany to test multiple doses of NOX-A12 with anti-VEGF and radiotherapy.

NOX-E36, our second clinical-stage asset, has demonstrated safety, tolerability, and promising pharmacokinetics/pharmacodynamics (PK/PD) as an anti-fibrotic treatment in ophthalmology. We plan to monetize NOX-E36 through a spinout or similar structure.

www.tmepharma.com

​VasoDynamics Ltd.

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as systemic cytotoxic therapies and radiotherapy induced mucositis, dermatitis, and hair-loss.

We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a platform of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during their journey of cancer treatments.

www.vasodynamics.co.uk

ViaNautis Bio Ltd.

ViaNautis Bio develops genetic medicines for CNS diseases, including epilepsy, Frontotemporal Dementia (FTD), and Parkinson’s, using proprietary PolyNaut® nanovesicles (PNVs). PNVs enable efficient delivery of DNA, ASO, and mRNA to the brain with high specificity, leveraging ligand-based targeting. We have demonstrated BBB crossing with angiopep2 PNVs, effectively targeting neurons and astrocytes without activating microglia. Compared to AAV and LNPs, PNVs offer re-dosing potential, 4°C stability, scalability, and large cargo capacity. ViaNautis is backed by leading investors, including 4BIO, BGF, UCBV, Lilly Ventures, and CFF, and has entered a multi-year, multi-target partnership with Eli Lilly to advance novel genetic medicines.​

www.vianautis.com

Rising Stars Session

Alpioner Therapeutics

Alpioner Therapeutics is a biotech company developing a new generation of vaccine candidates to fight against cancer and multi-resistant pathogens. Alpioner's proprietary bacterial platform leverages an inducible secretion system acting as a “microsyringe”, i.e. a potent antigen/functional protein delivery vectors capable of injecting efficiently and in high dose directly into the host cell cytosol.

Based on this platform, Alpioner Tx is developing a personalized therapeutic cancer vaccine which includes selected neoantigens and a first-in-class live attenuated vaccine candidate against Pseudomonas aeruginosa.
Alpioner’s mission is to save lives of patients suffering from difficult-to-treat cancers and from multi-resistant bacterial pathogens infections by developing highly immunogenic and strongly protective vaccine candidates.

Potent antigen/functional protein delivery vectors.

www.alpionertx.com

Amporin Pharmaceuticals AG

Amporin Pharmaceuticals was founded in Basel 2024 to develop a breakthrough new class of novel and proprietary small molecule "amyloid pore inhibitors", which can protect and repair cell membranes as the first actute oral disease-modifying treatments to stop and reverse the progression of at least 50 deadly degenerative diseases associated with protein misfolding and aggregation, including Alzheimer's, Parkinson's, and Huntington's disease, ALS, type II diabetes, and more than 40 rare neurodegenerative diseases. Our vision is to cure up to 6 major degenerative diseases, starting with Parkinson's disease and ALS, while our preliminary animal data already suggests that this is possible with a single acute oral dose of our prototype drug candidate.

www.amporin.com

ANNIMO Health EDC AG

ANNIMO Health EDC AG was founded to develop ""confirmed breakthrough"" therapies from early product stages into global market successes. We focus on newest IO therapies, next generation vaccines and anti-infectives from human health for animal health.

ANNIMO Health is a global company and an EDC, an Ethics Driven Company. We apply high standards of integrity, transparency and responsibilities for investors, family offices, PE and institutionals, VCs, employees, service partners, regulators, researchers, charities and animals.

www.meggen.ch

brainQr Therapeutics GmbH

brainQr Therapeutics is a pioneering biotechnology company redefining the treatment of devastating human diseases by targeting the dynamic proteome—disordered proteins that were long considered undruggable.

Core Technology:
brainQr leverages its cutting-edge AI-IDP platform to accelerate the discovery and development of groundbreaking therapies. By combining experimental precision with AI-driven innovation, brainQr unlocks therapeutic potential in areas previously unreachable.

Lead Program:
brainQr's flagship program focuses on stabilizing the native structure of the Tau protein by small molecules to combat Alzheimer’s disease. This first-in-class approach addresses the root cause of neurodegeneration by halting pathological aggregation and spreading of Tau.

Broader Impact:
The company’s innovative platform extends beyond Alzheimer’s disease, with applications across neurodegeneration, oncology, and rare diseases. brainQr is committed to transforming healthcare by addressing critical unmet medical needs globally.

www.braincuretherapeutics.com

FluoSphera SA

FluoSphera is transforming drug discovery with its groundbreaking human systemic in vitro platform. FluoSphera’s cutting-edge technology provides drug developers with unparalleled insights, enabling them to make data-driven decisions about which molecules to prioritize for clinical development. By improving efficiency, FluoSphera’s platform helps save time, reduce costs, and significantly minimize reliance on animal testing.

www.fluosphera.com

HHC Medical

HHC is developing first-in-class nucleic acid-based therapies (NATs) for anything from head and neck cancer to the future promise of curing Parkinson's disease. Our platform technology enables highly localized in vivo drug uptake with wireless electroporation. By using focused electromagnetic waves to manipulate the membrane of cells at a target site in the patient’s body, HHC enables a precise and highly localized drug uptake, while avoiding systemic side effects.​
​
www.hhc-medical.com

In Virtuo Laboratories SAGL

At InVirtuoLabs, we are revolutionizing drug discovery by seamlessly integrating cutting-edge artificial intelligence with molecular simulations. Our innovative platform combines advanced machine learning techniques—including multimodal learning, active learning, and generative chemistry—with physics-based simulations to explore vast chemical spaces with unprecedented efficiency. By leveraging this powerful synergy, we are able to rapidly identify and optimize promising drug candidates, dramatically accelerating the path from concept to life-changing therapies.​

www.invirtuolabs.com

MicThera Sagl

MicThera is a pioneering biotech startup developing microbial-inspired therapeutics to tackle resistance in prostate cancer and infectious diseases. 

In oncology, our lead program targets prostate cancer resistance pathways, backed by preclinical in-vivo efficacy data, addressing the urgent need for effective therapies in treatment-resistant disease forms. The efficacy of our oncology asset has been validated in other cancer types beyond prostate. 

In infectious diseases, we focus on novel antimicrobial peptides with potent activity against drug-resistant pathogens, with in vitro efficacy demonstrated. With the rise of antimicrobial resistance, our innovative approach offers promising solutions for combating life-threatening infections.

With exclusive licensing rights to patented technologies, proprietary patents, a founding team composed of world-leader scientists in prostate cancer and microbiota, we are positioned to advance products developed through a novel concept of targeting diseases by harnessing bacteria power.

Our proprietary discovery platform identifies and optimizes bioactive peptides from microbes, enabling the development of first-in-class treatments with novel mechanisms of action. The platform integrates AI-driven peptide mining and screening, cutting-edge research, and advanced screening to generate highly specific and effective therapeutics. This unique approach allows us to unlock the untapped potential of microbial peptides, offering a scalable pipeline of transformative treatments.

MicThera is actively seeking strategic partnerships to accelerate development, expand our pipeline, and bring our novel therapies to patients worldwide. We welcome collaborations with biopharma companies, investors, and research organizations to advance the next generation of microbial-inspired medicines.

www.micthera.com

Mighto Therapeutics

Mighto Therapeutics - New therapeutics for muscle and neurodegenerative disorders caused by mitochondrial dysfunction.​

www.mightotx.com

NatIgGs GmbH

Protein-misfolding diseases, like Alzheimer's, affect millions of people worldwide, yet effective treatment options remain elusive.

NatIgGs GmbH is an Ulm-based biotechnology startup company.

Our antibody 'rediscovery' platform integrates natural antibodies' wisdom and optimises antibodies using Artificial Intelligence /Machine Learning technologies to combat protein misfolding diseases.

This approach ensures our antibodies can precisely neutralize toxic proteins while sparing healthy ones, offering a superior level of therapeutic specificity.

www.natiggs.com

OncoBone Therapeutics Ltd

OncoBone Therapeutics develops novel therapies for cancer patients with bone metastases, a high unmet medical need.

www.oncobone.com

​PannTheraPi

Panntherapi is a clinical stage biotech company developing innovative drugs in Neurology by acting on a new specific target only involved in pathological processes. Our first in class clinical stage product (Phase 1 done, ready for phase 2) is indicated to treat a dramatic resistant epileptic syndrome mostly pediatric (2 patents + Orphan drug status). With our unique platform (AI, in vitro and ex vivo models using postoperative tissues from patients), we also identified new chemicals entities (1 patent) which will develop in other diseases of interest such as multiple sclerosis, pain, psychiatry or neurodegenerative diseases.

Laureate of the EIC Accelerator (grant + equity) among others, Panntherapi is a French company with a highly skilled team coming from pharma and biotech industries. We are looking for a seed funding to perform the proof of concept clinical trial in the orphan epileptic syndrome, and pursue the characterization of our other compounds. We already received expression of interest from 5 pharmaceutical companies (CDA signed) for a potential licensing of our compounds after the obtention of clinical data, validating the first candidate, the target and our platform.

www.panntherapi.com

Procavea Biotech AG

Procavea Biotech is a recently incorporated ETH Spin-off company developing a proprietary technology platform to solve the RNA delivery problem. The company's current focus is on siRNA-based drugs in the area of kidney disease, where it will develop a first drug product. Procavea's proprietary platform technology is the first of its kind - computationally-designed nonviral protein cages, specifically designed to delivery oligonucleotides into cells. The lack of delivery technologies is widely recognised as limiting the full commercial potential of RNA therapeutics. Procavea has the means to tackle this problem head on, providing much needed solutions to pharmaceutical companies and ultimately break down the barriers to get oligonucleotide drugs to patients in need.​

www.procavea.com

Scarlet Therapeutics Limited

Scarlet's mission is to pioneer the use of universal red blood cells, unmodified or modified, for the benefit of human health. The platform is applicable to blood transfusion indications and for the treatment of many diseases, including metabolic diseases, autoimmune conditions and cancer.  The initial focus for clinical proof of concept for our platform is the treatment of a number of metabolic diseases with high clinical unmet needs.

www.scarlet-tx.com

Serenatis Bio

Serenatis Bio is a start-up biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness with huge unmet need and commercial opportunity. Each drug has a different mechanism of action - targeting glutamate, mu-opioid and dopamine receptors - using precision medicine to identify which OCD patients will respond to which drug. Serenatis Bio has just launched a $1.3m pre-seed round for preclinical work - it has already secured a lead investor, signed a term sheet, and is now seeking co-investors to join the syndicate. 

www.serenatisbio.com

VectioPep

VECTIOPEP is a pre-clinical biotech company developing cancer immunotherapy based on antigen-specific T-cell activation.

Vectiopep is developing immunotherapy to treat micro-satellite stable colorectal cancer (MSS CRC) and immune-checkpoint-inhibitor refractory melanoma; leveraging patented peptide-based mRNA vector technology that enables induction of superior antigen-specific T-cell responses, by the selective homing to specific antigen-presenting immune cells of the spleen.

While currently pursued in cancer indications with high unmet medical needs, the technology is envisaged to have applicability beyond cancer such as in e.g. auto-immune diseases, etc.

We are seeking investors to join the Seed investment round to advance our lead-asset to clinical proof-of-concept (PoC). That will validate our technology and guide further applications in other disease indications within and beyond oncology. A PoC is also deemed to position  VECTIOPEP as an attractive partner or acquisition target for a wide range of mid-large cap pharma companies.

www.vectiopep.ee